Related Experiment Video
Updated: Jun 24, 2026

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
Published on: December 11, 2013
Beta blockers for peripheral arterial disease
S C V Paravastu1, D A Mendonca, A da Silva
1Manchester Royal Infirmary, Manchester, UK. sharathparavstu@googlemail.com
Objectives:
To quantify the potential harm of beta blockers in patients with peripheral arterial disease.
Materials And Methods:
All randomised controlled trials (RCTs) comparing beta blockers with placebo for the outcomes of claudication and maximal walking distance and time, calf blood flow, vascular resistance and skin temperature were searched using the Cochrane Controlled Trials Register, PubMed and CINAHL. Trials comparing different types of beta blockers were excluded.
Results:
Six RCTs fulfilling the above criteria, with a total of 119 patients, were included. The beta blockers studied were atenolol, propranolol, pindolol and metoprolol. None of the trials showed a statistically significant worsening effect of beta blockers on the outcomes measured. There were no reports of any adverse events with the beta blockers studied.
Conclusions:
Currently, there is no evidence to suggest that beta blockers adversely affect walking distance in people with intermittent claudication. Beta blockers should be used with caution if clinically indicated, especially in patients with critical ischaemia where acute lowering of blood pressure is contraindicated.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Antihypertensive Drugs: Types of β-Blockers
Heart Failure Drugs: β-Blockers